Q3 FY25 Earnings Results

LargestFastest profit growthFastest sales growth

Sector All sectorsAerospace & DefenseAutomobilesAviationBanksBeveragesCablesCapital GoodsCapital Goods - Electrical EquipmentCapital MarketsCastings, Forgings & FastnersChemicalsCommercial ServicesCommoditiesConstructionConsumer DiscretionaryConsumer DurablesConsumer GoodsConsumer ServicesDiamond, Gems and JewelleryDiversifiedEducationEnergyEngineering ServicesFast Moving Consumer GoodsFinancial ServicesFMCGFood ProductsForest MaterialsHealthcareHealthcare ServicesIndustrial ProductsIndustrialsInformation TechnologyInsuranceLeisure ServicesLogistics & CargoMediaMetals & MiningOil & GasPackagingPetroleum ProductsPowerPrinting & StationeryRealtyRetailServicesSteelTelecomTelecommunicationTextilesTradingTransportTransport ServicesUtilities Result Any resultBeatMissedIn lineNo estimate Clear filters 201–228 of 228

Company		Revenue (₹ Cr)			Profit (₹ Cr)		Per share		8Q profit
Symbol ↕	Sector ↕	Reported ↓	YoY ↕	QoQ ↕	Reported ↕	YoY ↕	EPS ↕	vs consensus ↕	Trend
SUVEN Suven Life Sciences Ltd	Healthcare	2	0.0%	down−33.3%	−39	n/a	−1.79	No estimate
Span Divergent Ltd	Healthcare	2	down−36.9%	down−32.1%	0	down−450.0%	−0.27	No estimate
DESHRAKSHAKAUSHDHALAYALTD	Healthcare	2	up+19.0%	up+58.0%	0	down−7.7%	0.27	No estimate
VIVANZABIOSCIENCESLTD	Healthcare	2	down−77.1%	down−50.0%	0	down−81.0%	0.01	No estimate
COLINZLABORATORIESLTD	Healthcare	1	down−14.0%	down−21.0%	0	down−54.5%	0.20	No estimate
AMBALALSA Ambalal Sarabhai Enterprises Ltd	Healthcare	1	up+254.5%	n/a	8	n/a	1.10	No estimate
WELCUREDRUGSPHARMACEUTICALSLTD Welcure Drugs & Pharmaceuticals Ltd	Healthcare	1	n/a	down−96.0%	0	n/a	0.00	No estimate
MEDICAPQ Medi Caps Ltd	Healthcare	0	down−91.5%	down−73.5%	0	down−115.4%	−0.21	No estimate
GENOMICVALLEYBIOTECHLTD	Healthcare	0	up+450.0%	up+4.8%	0	up+700.0%	0.52	No estimate
TRANSCHEMLTD	Healthcare	0	n/a	n/a	1	up+21.9%	1.14	No estimate
Transchem Ltd	Healthcare	0	n/a	n/a	1	up+21.9%	1.14	No estimate
VD VENMAXDRUGSPHARMACEUTICALSLTD Venmax Drugs & Pharmaceuticals Ltd	Healthcare	0	n/a	up+17.6%	−1	down−1,766.7%	−0.95	No estimate
CG RUBRAMEDICAMENTSLTD Centuple Global Ltd	Healthcare	0	down−41.2%	up+100.0%	0	down−133.3%	−0.04	No estimate
SHYAMAINFOLTD Shyama Computronics and Services Ltd	Healthcare	0	up+20.0%	0.0%	0	n/a	0.02	No estimate
ORTINGLOBE Ortin Global Ltd	Healthcare	0	down−78.6%	down−40.0%	0	n/a	−0.14	No estimate
CHEMOPHARMALABORATORIESLTD Starsource Multitrade Ltd	Healthcare	0	n/a	n/a	0	down−125.0%	−1.13	No estimate
TRIOCHEMPRODUCTSLTD	Healthcare	0	n/a	n/a	0	n/a	3.67	No estimate
CG GENESISIBRCINDIALTD CCME Global Ltd	Healthcare	0	n/a	down−100.0%	0	n/a	−0.02	No estimate
KABRADRUGSLTD	Healthcare	0	n/a	n/a	−1	n/a	−0.54	No estimate
BACILPHARMALTD	Healthcare	0	n/a	n/a	0	n/a	−0.10	No estimate
KAMRONLABORATORIESLTD Adline Chem Lab Ltd	Healthcare	0	n/a	n/a	0	n/a	−0.21	No estimate
RL REKVINALABORATORIESLTD Rekvina Labs Ltd	Healthcare	0	n/a	n/a	0	n/a	−0.02	No estimate
CG RAYMEDLABSLTD Cresanto Global Limited	Healthcare	0	n/a	n/a	0	n/a	−0.59	No estimate
MP MPS Pharmaa Ltd	Healthcare	0	n/a	n/a	0	n/a	−0.09	No estimate
ACHYUTHEALTHCARELTD	Healthcare	0	n/a	n/a	0	n/a	0.00	No estimate
NECLIFE Nectar Lifescience Ltd	Healthcare	0	down−100.0%	down−100.0%	8	up+300.0%	0.35	No estimate
TAKE Take Ltd	Healthcare	0	n/a	n/a	48	n/a	3.22	No estimate
HP Harleystreet Pharmaceuticals Ltd(merged)	Healthcare	—	n/a	n/a	151	up+18.9%	4.83	No estimate

About Q3 FY25 earnings data

When are Q3 FY25 results announced?

Q3 FY25 covers the Oct–Dec 2024 quarter. Indian listed companies have up to 45 days after a quarter closes to file their results — 60 days for the January–March quarter — so results arrive in a wave over the weeks that follow rather than all at once. A quarter that has only just ended will look sparse and fill in.

Why do some Q3 FY25 growth figures show "n/a" instead of a percentage?

Growth is left blank whenever the comparison period was not profitable. A percentage change measured from a loss is arithmetic without meaning — a swing from a ₹10 crore loss to a ₹10 crore profit is not "200% growth", and publishing it as such would flatter the company. The reported figures for both periods are still shown, so the change is there to read directly.

Does the beat/miss verdict cover every company?

No analyst consensus was available for Q3 FY25, so no beat/miss verdict is shown. Revenue and profit growth are taken from reported results and cover every company in the table.

What counts as an in-line result rather than a beat or a miss?

Reported earnings per share within ±2% of the consensus estimate. The band is set there because a tighter one classifies rounding as news, and a wider one swallows surprises that genuinely moved a stock.

Are the figures consolidated or standalone?

Consolidated where a company reports on that basis, standalone otherwise, with all money in ₹ crore. Figures are as filed by the company with the exchanges (NSE/BSE); they are not restated or adjusted.

What does the 8-quarter trend line show?

Quarterly net profit for the last eight quarters, oldest on the left, always ending on the quarter shown in the row. Two years covers both the seasonal shape of the business and its direction. The line breaks where a quarter is missing rather than drawing across the gap, so a break is a real absence of data and not a reported collapse.

How do I find only the companies that beat estimates in Q3 FY25?

Use the Result filter above the table and choose Beat, or sort by EPS surprise to rank every covered company by how far it landed from consensus. Both are reflected in the page URL, so a filtered view can be bookmarked or shared.

Figures are as reported by companies in their quarterly filings to the exchanges (NSE/BSE), in ₹ crore. Consolidated results are shown where a company reports them, otherwise standalone. Year-on-year and quarter-on-quarter growth is omitted where the comparison period was loss-making, since a percentage change from a negative base is not meaningful. Analyst consensus is an estimate, not a forecast of outcome.